Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 1926 - 1950 of 15130 in total
Dinoprost has been investigated in Headache.
Approved
Investigational
Matched Iupac: … (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]hept-5-enoic acid
Matched Categories: … Genito Urinary System and Sex Hormones …
A Rho kinase inhibitor with norepinephrine transport inhibitory activity that reduces production of aqueous As of December 18, 2017 the FDA approved Aerie Pharmaceutical's Rhopressa (netarsudil ophthalmic solution) 0.02% for the indication of reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Acting as both a rho...
Approved
Matched Description: … Acting as both a rho kinase inhibitor and a norepinephrine transport inhibitor, Netarsudil is a novel ... conventional trabecular pathway of aqueous humour outflow to act as an inhibitor to the rho kinase and
Matched Categories: … latanoprost and netarsudil ... Amino Acids, Peptides, and Proteins ... Antiglaucoma Preparations and Miotics …
Cyclic peptide antibiotic similar to viomycin. It is produced by Streptomyces capreolus.
Approved
Matched Categories: … Amino Acids, Peptides, and Proteins …
Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used intravenously to halt premature labor. Although initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form. Atobisan was developed by the Swedish...
Approved
Investigational
Matched Description: … Atosiban is an inhibitor of the hormones oxytocin and vasopressin. ... Although initial studies suggested it could be used as a nasal spray and hence would not require hospital ... Atosiban is licensed in proprietary and generic forms for the delay of imminent pre-term birth in pregnant …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Genito Urinary System and Sex Hormones ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Rifampin, also known as rifampicin, is a broad-spectrum antimicrobial that was first discovered in 1965 and clinically used in 1968. Rifampin is used to treat tuberculosis and works by inhibiting the microbial DNA-dependent RNA polymerase (RNAP).
Approved
Matched Description: … rifampicin, is a broad-spectrum antimicrobial [A263748] that was first discovered in 1965 [A263753] and ... [A263768] Rifampin is used to treat tuberculosis and works by inhibiting the microbial DNA-dependent …
Matched Categories: … Nucleic Acid Synthesis Inhibitors ... dapsone and rifampicin ... rifampicin and isoniazid ... dapsone, rifampicin and clofazimine ... rifampicin, ethambutol and isoniazid …
Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its ligand Substance P, which is released in the gut...
Approved
Investigational
Matched Description: … Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated ... Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and ... By blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system …
Matched Categories: … Antiemetics and Antinauseants ... Alimentary Tract and Metabolism …
Voxilaprevir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common...
Approved
Investigational
Matched Description: … mature virus: NS3, NS4A, NS4B, NS5A, and NS5B [A19643]. ... categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and ... genetic material into the following structural and nonstructural proteins required for assembly into …
Matched Categories: … Amino Acids, Peptides, and Proteins ... sofosbuvir, velpatasvir and voxilaprevir …
Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.
Approved
Investigational
Withdrawn
Matched Categories: … Amino Acids, Peptides, and Proteins ... Hormone Antagonists and Related Agents ... Antineoplastic and Immunomodulating Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Viomycin is a tuberactinomycin antibiotic that was used to treat Mycobacterium tuberculosis until it was replaced by the less toxic capreomycin. These drugs bind RNA in bacterial ribosomes and inhibit protein synthesis. Viomycin was derived from the actinomycete Streptomyces puniceus.
Approved
Matched Description: … These drugs bind RNA in bacterial ribosomes and inhibit protein synthesis. …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor.[A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada on July 18, 2013 and by the European Commission on June 30, 2014. Trametinib...
Approved
Matched Description: … Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and ... [A258298] It was later approved by Health Canada on July 18, 2013 [L45588] and by the European Commission ... currently approved to treat a variety of cancers with BRAF mutations, such as non-small cell lung cancer and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated...
Approved
Matched Description: … INR testing, and numerous drug-drug and drug-food interactions. ... atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism ... Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting …
Matched Categories: … Blood and Blood Forming Organs …
A tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides.
Approved
Investigational
Nutraceutical
Matched Iupac: … (2S)-2-amino-4-{[(1R)-1-[(carboxymethyl)carbamoyl]-2-sulfanylethyl]carbamoyl}butanoic acid
Matched Description: … for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and
Matched Categories: … Amino Acids, Peptides, and Proteins …
Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quantities of the...
Approved
Matched Iupac: … (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid
Matched Description: … produce sufficient quantities of the thyroid hormones T4 (tetraiodothyronine or thyroxine) and ... hypothyroidism begin to develop such as fatigue, increased heart rate, depression[A179620], dry skin and ... [F4633] T4 and T3 act on nearly every cell of the body, but have a particularly …
Matched Mixtures name: … Levothyroxine and Liothyronine Thyroid ... Levothyroxine and Liothyronine Thyroid ... Levothyroxine and Liothyronine Thyroid …
Matched Categories: … Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... levothyroxine sodium and iodine compounds ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Colfosceril palmitate is a synthetic pulmonary surfactant administered in infants with respiratory distress syndrome. It was part of the first generation of commercially available artificial surfactants. It was developed by Burroughs Wellcome and it was FDA approved on August 6, 1990. Nowadays colfosceril palmitate is under the state of canceled...
Approved
Investigational
Withdrawn
Matched Description: … [T70] It was developed by Burroughs Wellcome and it was FDA approved on August 6, 1990. …
A synthetic phospholipid used in liposomes and lipid bilayers for the study of biological membranes. It is used in commercial drug preparations to solubilize drugs for injection
Approved
Matched Description: … A synthetic phospholipid used in liposomes and lipid bilayers for the study of biological membranes. …
Matched Categories: … Indicators and Reagents …
Pentetreotide has been used in trials studying the diagnosis of Cushing's syndrome.
Approved
Investigational
Matched Iupac: … ]carbamoyl}methyl)(carboxymethyl)amino]ethyl}(carboxymethyl)amino)ethyl](carboxymethyl)amino}acetic acid
Matched Categories: … Indicators and Reagents ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
A naturally occurring alkaloid derived from the Pilocarpus plants, pilocarpine is a muscarinic acetylcholine agonist.[A262016, A262036] Pilocarpine is associated with parasympathomimetic effects by selectively working on muscarinic receptors. Pilocarpine is used to treat dry mouth and various ophthalmic conditions, including elevated intraocular pressure and glaucoma. The usage of glaucoma by...
Approved
Investigational
Matched Description: … intraocular pressure and glaucoma. ... [A262036] Pilocarpine is used to treat dry mouth and various ophthalmic conditions, including elevated …
Matched Categories: … Antiglaucoma Preparations and Miotics …
Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension (PAH). It was first approved by the FDA in 2013. Macitentan differs from its predecessor bosentan in part due to its lower risk of hepatotoxicity. A combination product (Opsynvi) comprising macitentan and tadalafil was approved...
Approved
Matched Description: … A combination product (Opsynvi) comprising macitentan and [tadalafil] was approved in Canada in October …
Matched Categories: … macitentan and tadalafil …
Atogepant is an oral antagonist of calcitonin gene-related peptide (CGRP) receptors indicated for the prevention of episodic migraine headaches. It was developed by AbbVie and received FDA approval under the brand name Qulipta in September 2021. While its approval was predated by two other members of the same drug family,...
Approved
Investigational
Matched Description: … [valproic acid] or [topiramate]) or beta-blockers (e.g. ... It was developed by AbbVie and received FDA approval under the brand name Qulipta in September 2021. ... ] While its approval was predated by two other members of the same drug family, namely [ubrogepant] and
Iron is a transition metal with a symbol Fe and atomic number 26. By mass, it is the most common element on Earth. Iron is an essential element involved in various metabolic processes, including oxygen transport, deoxyribonucleic acid (DNA) synthesis, and energy production in electron transport . Resulting from inadequate...
Approved
Matched Description: … essential element involved in various metabolic processes, including oxygen transport, deoxyribonucleic acid ... Iron is a transition metal with a symbol Fe and atomic number 26. ... (DNA) synthesis, and energy production in electron transport [A32514]. …
Dihydroergocristine is part of the ergoloid mixture products. It is a semisynthetic ergot alkaloid and thus, it is characterized by a structural skeleton formed by an alkaloid ergoline. To know more about ergoloid mixtures, please visit DB01049.
Approved
Experimental
Matched Description: … [L2637] It is a semisynthetic ergot alkaloid and thus, it is characterized by a structural skeleton formed …
Matched Categories: … Ergot Alkaloids and Derivatives …
Simoctocog alfa is a recombinant B-domain deleted (BDD) rFVIII produced in genetically modified human embryonic kidney (HEK) 293F cells. The harvested product is concentrated and purified by a series of chromatography steps. It is an antihemorrhagic agent used as a replacement therapy in individuals with Haemophilia A who lack the...
Approved
Matched Description: … replaced by a 16 amino acid linker. ... The harvested product is concentrated and purified by a series of chromatography steps. ... + A3-C1-C2 whereas the B-domain, present in the full-length plasma-derived FVIII, has been deleted and
Matched Categories: … Amino Acids, Peptides, and Proteins …
Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin...
Approved
Investigational
Matched Iupac: … (2R)-3-phenyl-2-{[(1r,4r)-4-(propan-2-yl)cyclohexyl]formamido}propanoic acid
Matched Description: … Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial ... Nateglinide is extensively metabolized in the liver and excreted in urine (83%) and feces (10%). ... insulin and appears to occur only in those naïve to oral antidiabetic agents. …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …
Carbocromen was marketed for use in Germany as a vasodilator, however, it has been discontinued due to the risk of arrhythmia development .
Approved
Withdrawn
On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Canadian market.[A669,L43942]
Approved
Withdrawn
Matched Iupac: … 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(propan-2-yl)pyridin-3-yl]-3,5-dihydroxyhept-6-enoic acid
Matched Description: … Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew …
Displaying drugs 1926 - 1950 of 15130 in total